Abstract
Luteinizing-Hormone Releasing-Hormone Receptors (LHRH-R) are overexpressed on a variety of reproductive cancers, and can therefore serve as targets for high mortality cancers like Triple Negative Breast Cancer (TNBC) and Ovarian Cancer1,2. Targeting of LHRH-R with agents linked to the natural receptor ligand, the decapeptide Luteinizing-Hormone Releasing-Hormone (LHRH), enables precise targeting of chemotherapeutics and radiometals to tumors bearing LHRH-R. Preclinical evaluations of the cisplatin analog, Pt-Mal-LHRH, has shown encouraging results in targeting and destroying TNBC cancer in murine studies as well as in vitro2. A second series of LHRH bearing agents, 99mTc-acdien-LHRH and 99mTc-Acdien-peg-LHRH, have shown high target fidelities to TNBC cell lines (4T1 and MDA-MB-231 cells) and may prove to be a potent tumor specific radio-imaging agent1. Using these agents, it could be possible to detect and destroy LHRH-R bearing tumors in earlier clinical stages and more effectively. When considered alongside the growing number of peptide drug conjugates (PDCs), a new and hopeful era of cancer treatment can be anticipated, one wherein malignant cells are targeted while neighboring healthy tissues are spared.
Semester/Year of Award
Spring 5-4-2022
Mentor
Margaret W. Ndinguri
Mentor Department Affiliation
Chemistry
Access Options
Restricted Access Thesis
Document Type
Bachelor Thesis
Degree Name
Honors Scholars
Degree Level
Bachelor's
Department
Chemistry
Recommended Citation
Elliott, Andrew S., "Luteinizing-Hormone Releasing Hormone Directed Cisplatin and 99mTc Imaging Agents, Progress and Future Steps" (2022). Honors Theses. 905.
https://encompass.eku.edu/honors_theses/905